Simbrinza - (1% ,0.2% ; Ophthalmic Suspension/Drops)

Generic Name	Brinzolamide and Brimonidine Tartrate	Innovator	Alcon
Dosage	1% ,0.2% ; Ophthalmic Suspension/Drops	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	SIMBRINZA is a fixed combination of a carbonic anhydrase inhibitor and an alpha-2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*******	*** / *********	*** **, ****	*******	********* ********	*** ****** *** ****

Chronology Of Events